Библиография. 
Исследование фазы 2 по изучению неоадъювантной терапии NOV-002 в комбинации с доксорубицином и циклофосфамидом с последующим назначением доцетаксела у пациентов с HER-2 негативным раком молочной железы клинической стадии II–III c

1. Cabello C.M., Lamore S.D., Bair W.B. III, Davis A.L., Azimian S.M., Wondrak G.T. (2011) DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma. Free Radic Res 45(3):276−292.

2. Montero A.J., Jassem J. (2011) Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 71(11): 1385−1396.

3. Wondrak G.T. (2009) Redox — directed can certher apeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 11(12): 3013−3069.

4. Irani K., Xia Y., Zweier J.L., Sollott S.J., Der C.J., Fearon E.R., Sundaresan M., Finkel T., Goldschmidt-Clermont P.J. (1997) Mitogenic signaling mediated by oxidants in Ras-transformed ?broblasts. Science 275(5306): 1649−1652.

5. Laurent A., Nicco C., Chereau C., Goulvestre C., Alexandre J., Alves A., Levy E., Goldwasser F., Panis Y., Soubrane O. et al (2005) Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 65(3): 948−956.

6. Rodrigues M.S., Reddy M.M., Sattler M. (2008) Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications. Antioxid Redox Signal 10(10):1813−1848.

7. Trachootham D., Lu W., Ogasawara M.A., Nilsa R.D., Huang P. (2008) Redox regulation of cell survival. Antioxid Redox Signal 10(8): 1343−1374.

8. Trachootham D., Zhou Y., Zhang H., Demizu Y., Chen Z., Pelicano H., Chiao P.J., Achanta G., Arlinghaus R.B., Liu J. et al (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10(3): 241−252.

9. Glorieux C., Dejeans N., Sid B., Beck R., Calderon P.B., Verrax J. (2011) Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. Biochem Pharmacol 82(10): 1384−1390.

10. He C., Tamimi R.M., Hankinson S.E., Hunter D.J., Han J. (2009) A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk. Breast Cancer Res Treat 113(3): 585−594.

11. Yang J.C., Lu M.C., Lee C.L., Chen G.Y., Lin Y.Y., Chang F.R., Wu Y.C. (2011) Selective targeting of breast cancer cells through ROS-mediated mechanisms potentiates the lethality of paclitaxel by a novel diterpene, gelomulide K. Free Radic Biol Med 51(3): 641−657.

12. Townsend D.M., He L., Hutchens S., Garrett T.E., Pazoles C.J., Tew K.D. (2008) NOV-002, a glutathione disul? de mimetic, as a modulator of cellular redox balance. Cancer Res 68(8):2870 -2877.

13. Townsend DM, Pazoles CJ, Tew KD (2008) NOV-002, a mimetic of glutathione disul? de. Expert Opin Investig Drugs 17(7): 1075−1083.

14. Townsend D.M., Tew K.D. (2009) Pharmacology of a mimetic of glutathione disul? de, NOV-002. Biomed Pharmacother 63(2): 75−78.

15. Brigelius-Flohe R. (2006) Glutathione peroxidases and redox-regulated transcription factors. Biol Chem 387(10−11): 1329−1335.

16. Giles G.I. (2006) The redox regulation of thiol dependent signaling pathways in cancer. Curr Pharm Des 12(34):4427−4443.

17. Tew K.D., Manevich Y., Grek C., Xiong Y., Uys J., Townsend D.M. (2011) The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer. Free Radic Biol Med 51(2): 299−313.

18. Townsend D.M. (2007) S-glutathionylation: indicator of cell stress and regulator of the unfolded protein response. Mol Interv 7(6): 313−324.

19. Gumireddy K., Pazoles C., Vulfson E. (2009) Inhibition of tumor cell invasion and ErbB2/PI3 K signalling pathways by the glutathione disul? de-mimetic NOV-002. Proceedings of the 100^th annual meeting of the American Association for Cancer Research, 2009 (Abstract).

20. Townsend D.M., Bowers R., Pazoles C.J. (2009) NOV-002 suppresses tumor cell growth by modulating redox-sensitive cell signaling. Mol Cancer Ther 8(12 Suppl. 1) (Abstract C30).

21. Bowers R., Townsend D., Manevich Y. (2010) The redox modulator NOV-002 inhibits proliferation of ovariantumor cells but increases proliferation of myeloid cells. Proceedings of the 101^st annual meeting of the American Association for Cancer Research, 2010 (Abstract).

22. Montero A.J., Naga O., Xu M. (2009) Nov-002, a cellular redox modulator, enhances the antitumor effect of adoptively transferred T cells in a murine melanoma model. Mol Cancer Ther 8(12 Suppl. 1) (Abstract C238).

23. Krasner C.N., Seiden M.V., Penson R.T. (2008) NOV-002 plus carboplatin in platinum-resistant ovarian cancer. J. Clin Oncol 26 (Abstract).

24. Bear H.D., Anderson S., Brown A., Smith R., Mamounas E.P., Fisher B, Margolese R., Theoret H., Soran A., Wickerham D.L. et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21(22): 4165−4174.

25. Bear H.D., Anderson S., Smith R.E., Geyer C.E. Jr., Mamounas E.P., Fisher B., Brown A.M., Robidoux A., Margolese R., Kahlenberg M.S. et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24(13): 2019;2027.

26. Symmans W.F., Peintinger F., Hatzis C., Rajan R., Kuerer H., Valero V., Assad L., Poniecka A., Hennessy B., Green M. et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28): 4414−4422.

27. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58(1): 49−59.

28. Solito S., Falisi E., Diaz-Montero C.M., Doni A., Pinton L., Rosato A., Francescato S., Basso G., Zanovello P., Onicescu G. et al. (2011) A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (Journal Article).

29. Koyama T., Chen H. (2008) Proper inference from Simon’s two-stage designs. Stat Med 27(16): 3145−3154.

30. Straver M.E., Rutgers E.J., Rodenhuis S., Linn S.C., Loo C.E., Wesseling J., Russell N.S., Oldenburg H.S., Antonini N., Vrancken Peeters M.T. (2010) The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol 17(9): 2411−2418.

31. Tolaney S.M., Najita J., Winer E.P., Burstein H.J. (2008) Lymphopenia associated with adjuvant anthracycline/taxane regimens. Clin Breast Cancer 8(4): 352−356.

32. Ayers M., Symmans W.F., Stec J., Damokosh A.I., Clark E., Hess K., Lecocke M., Metivier J., Booser D., Booser D., Ibrahim N. et al (2004) Gene expression pro? les predict complete pathologic response to neoadjuvant paclitaxel and? uorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22(12): 2284−2293.

33. Carey L.A., Metzger R., Dees E.C., Collichio F., Sartor C.I., Ollila D.W., Klauber-DeMore N., Halle J., Sawyer L., Moore D.T. et al (2005) American joint committee on cancer tumor-node-metas-tasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 97(15): 1137−1142.

34. Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R., Wickerham D.L., Begovic M., DeCillis A., Robidoux A. et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16(8): 2672−2685.

35. Gonzalez-Angulo A.M., McGuire S.E., Buchholz T.A., Tucker S.L., Kuerer H.M., Rouzier R., Kau S.W., Huang E.H., Morandi P., Ocana A. et al (2005) Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 23(28): 7098−7104.

36. Heys S.D., Sarkar T., Hutcheon A.W. (2005) Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival. Breast Cancer Res Treat 90(2): 169−185.

37. Kuroi K., Toi M., Tsuda H., Kurosumi M., Akiyama F. (2006) Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer 13(1): 38−48.

38. Mazouni C., Kau S.W., Frye D., Andre F., Kuerer H.M., Buchholz T.A., Symmans W.F., Anderson K., Hess K.R., Gonzalez-Angulo A.M. et al (2007) Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 18(5): 874−880.

39. GluЁck S., Ross J.S., Royce M., McKenna E.F., Jr., Perou C.M., Avisar E., Wu L. (2011) TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Can-cer Res Treat (Journal Article).

40. GluЁck S., McKenna E.F. Jr, Royce M. (2008) XeNA: capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer. Int J Med Sci 5(6): 341−346.

41. von Minckwitz G., Raab G., Caputo A., Schutte M., Hilfrich J., Blohmer J.U., Gerber B., Costa S.D., Merkle E., Eidtmann H. et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J. Clin Oncol 23(12): 2676−2685.

42. Wolmark N., Wang J., Mamounas E., Bryant J., Fisher B. (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001(30): 96−102.

43. Guarneri V., Broglio K., Kau S.W., Cristofanilli M., Buzdar A.U., Valero V., Buchholz T., Meric F., Hortobagyi GN et al (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24(7):1037−1044.

44. Montero A., Fossella F., Hortobagyi G., Valero V. (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6(4): 229−239.

45. Ruscoe J.E., Rosario L.A., Wang T., Gate L., Arifoglu P., Wolf C.R., Henderson C.J., Ronai Z., Tew K.D. (2001) Pharmacologic or genetic manipulation of glutathioneS-transferase P1−1 (GSTpi) in? uences cell proliferation pathways. J Pharmacol Exp Ther 298(1): 339−345.

46. Pazoles CJ, Gerstein H (2006) NOV-002, a chemoprotectant/ immunomodulator, added to? rst-line carboplatin/paclitaxel in advanced non-small cell lung cancer (NSCLC): a randomized phase ½, open-label, controlled study. J Clin Oncol 24(18S): Pt 1(June 20 Suppl): 668S, (Abstract #17 021).

47. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., Castedo M., Mignot G., Panaretakis T., Casares N. et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1): 54−61.

48. Tesniere A., Apetoh L., Ghiringhelli F., Joza N., Panaretakis T., Kepp O., Schlemmer F., Zitvogel L., Kroemer G. (2008) Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 20(5): 504−511.

49. Mandruzzato S., Solito S., Falisi E., Francescato S., Chiarion-Sileni V., Mocellin S., Zanon A., Rossi C.R., Nitti D., Bronte V. (2009) IL4Ralpha? myeloid-derived suppressor cell expansion in cancer patients. J Immunol 182(10): 6562−6568.

50. Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59(10): 1593−1600.

51. Gabitass R.F., Annels N.E., Stocken D.D., Pandha H.A., Middleton G.W. (2011) Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with signi? cant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 60(10): 1419−1430.

52. Finkelstein S.E., Carey T., Fricke I., Yu D., Goetz D., Gratz M., Dunn M., Urbas P., Daud A., DeConti R. et al (2010) Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother 33(8):817−827.